NO20074199L - Nye farmasoytiske blandinger som er nyttige i behandlingen av Parkinsons sykdom - Google Patents

Nye farmasoytiske blandinger som er nyttige i behandlingen av Parkinsons sykdom

Info

Publication number
NO20074199L
NO20074199L NO20074199A NO20074199A NO20074199L NO 20074199 L NO20074199 L NO 20074199L NO 20074199 A NO20074199 A NO 20074199A NO 20074199 A NO20074199 A NO 20074199A NO 20074199 L NO20074199 L NO 20074199L
Authority
NO
Norway
Prior art keywords
treatment
parkinson
disease
pharmaceutical compositions
compositions useful
Prior art date
Application number
NO20074199A
Other languages
English (en)
Norwegian (no)
Inventor
Anders Pettersson
Thomas Lundqvist
Original Assignee
Orexo Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orexo Ab filed Critical Orexo Ab
Publication of NO20074199L publication Critical patent/NO20074199L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20074199A 2005-03-28 2007-08-16 Nye farmasoytiske blandinger som er nyttige i behandlingen av Parkinsons sykdom NO20074199L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66537605P 2005-03-28 2005-03-28
PCT/GB2006/001132 WO2006103417A1 (en) 2005-03-28 2006-03-28 New pharmaceutical compositions useful in the treatment of parkinson's disease

Publications (1)

Publication Number Publication Date
NO20074199L true NO20074199L (no) 2007-11-21

Family

ID=34956744

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20074199A NO20074199L (no) 2005-03-28 2007-08-16 Nye farmasoytiske blandinger som er nyttige i behandlingen av Parkinsons sykdom

Country Status (13)

Country Link
US (1) US20080193526A1 (es)
EP (1) EP1863455A1 (es)
JP (1) JP2008534563A (es)
KR (1) KR20070114734A (es)
CN (1) CN101141949B (es)
AU (1) AU2006228296B2 (es)
CA (1) CA2599384A1 (es)
IL (1) IL185300A0 (es)
MX (1) MX2007011976A (es)
NO (1) NO20074199L (es)
NZ (1) NZ560826A (es)
RU (1) RU2440100C2 (es)
WO (1) WO2006103417A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
AR055106A1 (es) * 2005-08-05 2007-08-08 Osmotica Pharmaceutical Argent Composicion farmaceutica solida de liberacion extendida que contiene carbidopa y levodopa
US8741918B2 (en) 2007-06-21 2014-06-03 Veroscience Llc Parenteral formulations of dopamine agonists
US20100035886A1 (en) 2007-06-21 2010-02-11 Veroscience, Llc Parenteral formulations of dopamine agonists
CN101910113A (zh) * 2007-12-28 2010-12-08 怡百克制药公司 左旋多巴控释制剂及其用途
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
US20140335139A1 (en) 2013-05-13 2014-11-13 NeuOra Microceuticals, LLC Long lasting breath mint
KR101850479B1 (ko) 2015-07-22 2018-05-30 (주)듀켐바이오 [18F]플루오로-도파의 중성 pH 안정화 방법
RU2697411C2 (ru) * 2017-10-11 2019-08-14 федеральное государственное автономное образовательное учреждение высшего образования Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский университет) Композиция для лечения болезни Паркинсона

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5414167B1 (es) * 1970-12-28 1979-06-05
SE8800080L (sv) * 1988-01-13 1989-07-14 Kabivitrum Ab Laekemedelskomposition
DE4101873C2 (de) * 1991-01-23 1993-12-09 Isis Pharma Gmbh Peroral applizierbare Arzneiform zur Behandlung zentraler Dopaminmangelzustände
HU209564B (en) * 1991-01-30 1994-07-28 Egyt Gyogyszervegyeszeti Gyar Process for producing rapide tablets containing levodopa and carbidopa
US6566368B2 (en) * 1994-04-22 2003-05-20 Pentech Pharmaceuticals, Inc. Apomorphine-containing dosage form for ameliorating male erectile dysfunction
US5840756A (en) * 1995-07-21 1998-11-24 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition of L-DOPA ester
GB9517062D0 (en) * 1995-08-18 1995-10-25 Scherer Ltd R P Pharmaceutical compositions
SE9803240D0 (sv) * 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action
US6531153B2 (en) * 2001-05-29 2003-03-11 Drugtech Corporation Composition with sustained release of levodopa and carbidopa
NZ541167A (en) * 2003-01-31 2008-07-31 Orexo Ab A rapid-acting pharmaceutical composition comprising e.g. fentanyl and particles insoluble in water
CA2522231A1 (en) * 2003-04-14 2004-10-21 Vectura Ltd Pharmaceutical compositions comprising apomorphine for pulmonary inhalation

Also Published As

Publication number Publication date
WO2006103417A1 (en) 2006-10-05
CN101141949B (zh) 2010-12-08
EP1863455A1 (en) 2007-12-12
RU2007139826A (ru) 2009-05-10
IL185300A0 (en) 2008-02-09
AU2006228296B2 (en) 2011-08-04
AU2006228296A1 (en) 2006-10-05
CN101141949A (zh) 2008-03-12
RU2440100C2 (ru) 2012-01-20
JP2008534563A (ja) 2008-08-28
MX2007011976A (es) 2007-12-07
KR20070114734A (ko) 2007-12-04
CA2599384A1 (en) 2006-10-05
NZ560826A (en) 2009-06-26
US20080193526A1 (en) 2008-08-14

Similar Documents

Publication Publication Date Title
NO20074199L (no) Nye farmasoytiske blandinger som er nyttige i behandlingen av Parkinsons sykdom
DK1525177T3 (da) Substituerede 1,3-diphenylprop-2-en-1-on-derivater, fremstilling og anvendelse deraf
UY27755A1 (es) Nuevas composiciones farmacéuticas basadas en anticolinérgicos e inhibidores.
BR0012804A (pt) Derivados de amina e amida como ligandos para o receptor de neuropeptìdeo y y5 útil no tratamento da obesidade e outros distúrbios
AR037996A1 (es) Compuesto derivado de amino nicotinato, composicion farmaceutica; proceso para su preparacion y su uso como medicamento
BR0307351A (pt) Composto, composição farmacêutica, método para tratar uma condição ou estado de doença mediados pela atividade de p38 quinase ou mediados por citocinas produzidas pela atividade de p38 quinase, uso de um composto, e, processo para preparar um composto
BRPI0412054A (pt) preparação farmacêutica transdérmica
PT1119543E (pt) N-aralquilaminotetralinas como ligandos para o receptor y5 do neuropeptido y
ZA992951B (en) N-substituted aminotetralins as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders.
WO2007048066A3 (en) Pyrazolo-pyrimidines as casein kinase ii (ck2) modulators
GEP20084435B (en) Substituted pyrrolo-pyrazole derivatives as kinase inhibitors
EP1508570A4 (en) NEW PHYSIOLOGICAL ACTIVE SUBSTANCES
TW200716628A (en) Novel compounds
DE60315479D1 (de) Pyrimidinamid derivate und deren verwendung
PE20110677A1 (es) Polimorfo b de la n-(2-aminofenil)-4-[n-(piridin-3-il) metoxicarbonilamino-metil]benzamida (ms-275)
ATE505203T1 (de) Pharmazeutische kombination aus aliskiren und valsartan
DK1511489T3 (da) Nye farmaceutiske sammensætninger indeholdende flibanserin-polymorf A
TNSN07337A1 (en) Pharmaceutical composition comprising an indolylmaleimide derivative
EP1379508A4 (en) N- (ARYL) -2-ARYLETHESULFONAMIDES AND THEIR THERAPEUTIC APPLICATIONS
IL163951A (en) Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them
PL1876169T3 (pl) Pochodne amin n-acylowych i aminokwasów zawierające fenyl, sposoby ich wytwarzania, kompozycje farmaceutyczne i ich zastosowanie
BRPI0417946A (pt) composto, métodos para o tratamento ou a profilaxia de uma doença ou condição, e de distúrbios, e para a indução da cessação do hábito de fumar, composição farmacêutica, e, uso de um composto
BRPI0514579A (pt) composto, composição farmacêutica, uso de um composto, combinação de um composto e gaboxadol, e, processo para preparo de um composto
CA2526385A1 (en) Continuous dosing regimen with abt-751
FR2883876B1 (fr) Derives d'indanyl-piperazines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application